Concepedia
Statistics
Publications
27
Citations
4.8K
H-Index
22
Active since
1997
Affiliations
National Cancer Institute(Current)
Center for Cancer Research
National Institutes of Health
MacroGenics (United States)
Carolina BioOncology Institute
James R. Vasselli is an author at National Cancer Institute specializing in oncology, medicine, and molecular oncology.
Publications per year
1997–2016
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text
Medicine, Oncology, Pharmacology +6
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Samuel A. Wells, Jessica E. Gosnell, Robert F. Gagel et al. · Journal of Clinical Oncology · 2010 · 517 citations · Full text
Medicine, Oncology, Pharmacology +17
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
Jodi K. Maranchie, James R. Vasselli, Joseph Riss et al. · Cancer Cell · 2002 · 435 citations · Full text
Medicine, Molecular Biology, Oncology +16
Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Bruce G. Robinson, Luis Paz‐Ares, Annetta Krebs et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 255 citations · Full text
Medicine, Oncology, Pharmacology +13
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
John V. Heymach, Luis Paz‐Ares, Filippo de Braud et al. · Journal of Clinical Oncology · 2008 · 220 citations
1–5 of 27